Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
NCT ID: NCT00484419
Last Updated: 2016-10-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
169 participants
INTERVENTIONAL
2007-05-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin
NCT00501020
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
NCT00367055
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00044460
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
NCT00499707
Rosiglitazone to Reverse Metabolic Defects in Diabetes
NCT00094796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
colesevelam
colesevelam tablets 625 mg
Colesevelam HCl
coleveselam tablets 625 mg; 6 tablets/day
rosiglitazone
rosiglitazone maleate 4mg
rosiglitazone maleate
rosiglitazone tablets 4mg
sitagliptin
sitagliptin phosphate tablets
sitagliptin phosphate
sitagliptin phosphate tablets 100mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colesevelam HCl
coleveselam tablets 625 mg; 6 tablets/day
rosiglitazone maleate
rosiglitazone tablets 4mg
sitagliptin phosphate
sitagliptin phosphate tablets 100mg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Mesa, California, United States
Los Angeles, California, United States
Los Gatos, California, United States
San Antonio, California, United States
Chiefland, Florida, United States
Gary, Indiana, United States
Baltimore, Maryland, United States
Dearborn, Michigan, United States
West Bloomfield, Michigan, United States
Las Vegas, Nevada, United States
Yonkers, New York, United States
Lexington, North Carolina, United States
Winston-Salem, North Carolina, United States
Munroe Falls, Ohio, United States
Zaneville, Ohio, United States
Portland, Oregon, United States
Jersey Shore, Pennsylvania, United States
Clemson, South Carolina, United States
Harriman, Tennessee, United States
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Wel-409
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.